{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:18:14Z","timestamp":1791310694680,"version":"4.3.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>OCs play a crucial role in myeloma-induced immunosuppressive microenvironment. Therapeutic anti-CD38 mAb partially overcomes the immunosuppressive effect of OCs.<\/jats:p>","DOI":"10.1182\/blood-2016-03-707547","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T03:23:57Z","timestamp":1468553037000},"page":"1590-1603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":173,"title":["Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication"],"prefix":"10.1182","volume":"128","author":[{"given":"Gang","family":"An","sequence":"first","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"},{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Acharya","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Feng","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"},{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zhong","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111704594605600_B1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111704594605600_B2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma.","volume":"17","author":"Raje","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111704594605600_B3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmed.2014.06.001","article-title":"Osteoclasts: more than \u2018bone eaters\u2019.","volume":"20","author":"Charles","year":"2014","journal-title":"Trends Mol Med"},{"issue":"3","key":"2019111704594605600_B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/08916930701693180","article-title":"Osteoclasts - the innate immune cells of the bone.","volume":"41","author":"Wu","year":"2008","journal-title":"Autoimmunity"},{"issue":"12","key":"2019111704594605600_B5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrrheum.2009.217","article-title":"Osteoimmunology and the effects of the immune system on bone.","volume":"5","author":"Takayanagi","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"6812","key":"2019111704594605600_B6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature"},{"issue":"4","key":"2019111704594605600_B7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jcp.22411","article-title":"T cell suppression by osteoclasts in vitro.","volume":"226","author":"Grassi","year":"2011","journal-title":"J Cell Physiol"},{"issue":"36","key":"2019111704594605600_B8","doi-asserted-by":"crossref","first-page":"14436","DOI":"10.1073\/pnas.0702811104","article-title":"CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts.","volume":"104","author":"Cui","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111704594605600_B9","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/leu.2015.62","article-title":"The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.","volume":"29","author":"Coles","year":"2015","journal-title":"Leukemia"},{"issue":"15","key":"2019111704594605600_B10","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111704594605600_B11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2019111704594605600_B12","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111704594605600_B13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells.","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111704594605600_B14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111704594605600_B15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy.","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"20","key":"2019111704594605600_B16","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111704594605600_B17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111704594605600_B18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: an emerging key player in the mammalian immune system.","volume":"158","author":"Munder","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"21","key":"2019111704594605600_B19","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.1073\/pnas.1402914111","article-title":"Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes.","volume":"111","author":"Shand","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111704594605600_B20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"issue":"12","key":"2019111704594605600_B21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"1","key":"2019111704594605600_B22","first-page":"177","article-title":"Galectin-9 in tumor biology: a jack of multiple trades.","volume":"1836","author":"Heusschen","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2019111704594605600_B23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111704594605600_B24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111704594605600_B25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood-2010-04-279760","article-title":"Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.","volume":"117","author":"Moreaux","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111704594605600_B26","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111704594605600_B27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111704594605600_B28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"2019111704594605600_B29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMe1509419","article-title":"Monoclonal antibodies in multiple myeloma come of age.","volume":"373","author":"Raje","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111704594605600_B30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma.","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111704594605600_B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2019111704594605600_B32","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma.","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"issue":"9","key":"2019111704594605600_B33","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","article-title":"Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.","volume":"120","author":"Tai","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111704594605600_B34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2019111704594605600_B35","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"issue":"7528","key":"2019111704594605600_B36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"5","key":"2019111704594605600_B37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"2019111704594605600_B38","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma.","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111704594605600_B39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets.","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2019111704594605600_B40","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.","volume":"176","author":"Fallarino","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"2019111704594605600_B41","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/jbmr.2294","article-title":"Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-\u03b3 and CD40 ligand in vitro.","volume":"29","author":"Li","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2019111704594605600_B42","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","article-title":"Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow.","volume":"118","author":"Matthes","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111704594605600_B43","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2015.145","article-title":"Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"key":"2019111704594605600_B44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0105-2896.2005.00336.x","article-title":"Osteoclast precursors, RANKL\/RANK, and immunology.","volume":"208","author":"Xing","year":"2005","journal-title":"Immunol Rev"},{"issue":"12","key":"2019111704594605600_B45","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1172\/JCI60920","article-title":"Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function.","volume":"122","author":"Charles","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111704594605600_B46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-12-2202","article-title":"Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res"},{"issue":"11","key":"2019111704594605600_B47","doi-asserted-by":"crossref","first-page":"e48871","DOI":"10.1371\/journal.pone.0048871","article-title":"Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.","volume":"7","author":"Zhuang","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"2019111704594605600_B48","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","article-title":"CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer.","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"2019111704594605600_B49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","article-title":"Tumor necrosis factor-\u03b1 blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.","volume":"38","author":"Sade-Feldman","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"2019111704594605600_B50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1096\/fj.02-0205com","article-title":"Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption.","volume":"17","author":"Sun","year":"2003","journal-title":"FASEB J"},{"issue":"1","key":"2019111704594605600_B51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00774-005-0642-3","article-title":"CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.","volume":"24","author":"Drummond","year":"2006","journal-title":"J Bone Miner Metab"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/12\/1590\/1396146\/1590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/12\/1590\/1396146\/1590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:00:05Z","timestamp":1573984805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/12\/1590\/73140\/Osteoclasts-promote-immune-suppressive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-707547","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}